An AI Experiment at the FDA & Novo Trailing in the Obesity Drug Race
6 Articles
6 Articles
An AI experiment at the FDA & Novo trailing in the obesity drug race
On this week’s episode of “The Readout LOUD”: The Food and Drug Administration’s AI adventure, a deep look inside Novo Nordisk’s obesity stumble, and finally, another big M&A deal in biotech. The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can’t seem to let go of mistakes. Our colleague Brittany Trang joins to explain. And it’s always a fun podcast when we can discuss a biotech acquisition. This…
FDA launches AI tool for its employees
The FDA launched Elsa, a generative AI tool designed to help employees, including scientific reviewers and investigators, work more efficiently. In a statement, the agency said the tool “modernizes agency functions and leverages AI capabilities to serve the American people better.” Constructed in a high-security government cloud environment, Elsa provides a platform for FDA employees to access internal documents, while ensuring that all informat…
FDA Introduces AI Tool Elsa to Aid Drug Approvals and Food Safety Monitoring
The U.S. Food and Drug Administration (FDA) has introdu […] The post FDA Introduces AI Tool Elsa to Aid Drug Approvals and Food Safety Monitoring first appeared on GeneOnline News. The post FDA Introduces AI Tool Elsa to Aid Drug Approvals and Food Safety Monitoring appeared first on GeneOnline News.
The Week in AgriFoodTech: India's Udaan scores $340m, climate forecaster Jua nabs $11m, FDA launches AI tool
Notable fundraises this week came from Indian B2B trading platform Udaan, Swiss climate-forecasting startup Jua, and Japan-based “hot chain” foodservice startup Wada FoodTech, best known for its automated bento vending machines. Elsewhere, Israeli plant-based manufacturer Meala teamed up with DSM-Firmenich to launch texturizing protein for meat alternatives, while Big Idea Ventures and Mars Petcare launched a global pet food innovation program. …
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage